Gastric Adenocarcinomas with CDX2 Induction Show Higher Frequency of TP53 and KMT2B Mutations and MYC Amplifications but Similar Survival Compared with Cancers with No CDX2 Induction.

J Clin Med · 2024 · PMC11727917 · PMID 39768557

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.09so close (0.05 < p ≤ 0.1)

ERBB2 amplifications also showed a trend for higher prevalence in the higher CDX2-expressing group (14.7% versus 6.5% in the CDX2-lower-expressing group, Fisher’s exact test p = 0.09, Figure 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Gastric Adenocarcinomas with CDX2 Induction Show Higher Frequency of <i>TP53</i> and <i>KMT2B</i> Mutations and <i>MYC</i> Amplifications but Similar Survival Compared with Cancers with No CDX2 Induction.

The sentences